Nation wide cohort study of Japanese patients with ANCA associated vasculitis using rituximab Effectiveness and safety after two years
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf052 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Kenji Nagasaka und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Ome Medical Center, Ome, Japan. Hauptthemen laut MEDLINE: Rituximab, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Immunologic Factors, Granulomatosis with Polyangiitis. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Ministry of Health, Japan Agency for Medical Research and Development, Ministry of Health, Labour and Welfare, Japan.
Abstract (Originalsprache)
Objectives
To evaluate the efficacy and safety of rituximab (RTX) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in Japan.
Methods
Patients with MPA and GPA treated with RTX at each institution were enrolled and followed-up prospectively. Two years of data were analysed.
Results
Seventy-five patients were received RTX for remission induction therapy and 57 were observed beyond 6 months. Thirty-five did and 22 did not receive any additional RTX treatment. RTX dosing patterns were diverse. During the 2-year observation period, 56 (74.7%) patients achieved remission; however, 11 (19.6%) patients relapsed. Five patients experienced major relapses, three experienced minor relapses, and three experienced unclassified relapses. Of the 75 patients treated with RTX as remission induction therapy, 63 severe adverse events (SAEs) were observed in 33 patients during the 2-year observation period. Thirty-nine SAEs occurred by 6 months and 24 SAEs were observed after 6 months. Of the 12 patients with SAEs after 6 months, four received RTX after 6 months, resulting in six events. The most common SAE was infection during the first 6 months and after 6 months.
Conclusions
The effectiveness and safety of RTX for MPA and GPA in Japan were demonstrated over a 2-year observation period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Ome Medical Center, Ome, Japan.
- Department of Rheumatology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
- Department of Rheumatology and Allergology, St. Marianna University School of Medicine, Kawasaki, Japan.
- Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
- Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan.
Förderung
- Ministry of Health
- Japan Agency for Medical Research and Development
- Ministry of Health, Labour and Welfare, Japan
Zitieren
APA
Nagasaka, K., Amano, K., Nagafuchi, H., Sada, K. E., Komagata, Y., Yamamura, M., Kato, M., Endo, T., Nakaya, I., Takeuchi, T., Murakawa, Y., Sugihara, T., Saito, M., Hayashi, T., Furuta, S., Karasawa, K., Banno, S., Endo, S., Majima, M., …, & Harigai, M. (2025). Nation wide cohort study of Japanese patients with ANCA associated vasculitis using rituximab Effectiveness and safety after two years. Modern Rheumatology. https://doi.org/10.1093/mr/roaf052
Vancouver
Nagasaka K, Amano K, Nagafuchi H, Sada KE, Komagata Y, Yamamura M, et al. Nation wide cohort study of Japanese patients with ANCA associated vasculitis using rituximab Effectiveness and safety after two years. Modern Rheumatology. 2025. doi:10.1093/mr/roaf052
BibTeX
@article{Nagasaka2025,
author = {Nagasaka, Kenji and Amano, Koichi and Nagafuchi, Hiroko and Sada, Ken-Ei and Komagata, Yoshinori and Yamamura, Masahiro and Kato, Masaru and Endo, Tomomi and Nakaya, Izaya and Takeuchi, Tsutomu and Murakawa, Yohko and Sugihara, Takahiko and Saito, Masaya and Hayashi, Taichi and Furuta, Shunsuke and Karasawa, Kazunori and Banno, Shogo and Endo, Shuichiro and Majima, Masako and Dobashi, Hiroaki and Kaname, Shinya and Tamura, Naoto and Arimura, Yoshiriro and Harigai, Masayoshi},
title = {Nation wide cohort study of Japanese patients with ANCA associated vasculitis using rituximab Effectiveness and safety after two years},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf052}
}
EUVIMED